{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:33:43Z","timestamp":1786991623333,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000082","name":"Cystic Fibrosis Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000082","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jcf.2023.05.015","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T03:17:40Z","timestamp":1697858260000},"page":"109-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Elexacaftor-tezacaftor-ivacaftor increases airway nitric oxide in children with cystic fibrosis"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4886-189X","authenticated-orcid":false,"given":"Isaac","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4057-6592","authenticated-orcid":false,"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-9642","authenticated-orcid":false,"given":"Hartmut","family":"Grasemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jcf.2023.05.015_bib0001","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/adc.75.4.319","article-title":"Reduced upper airway nitric oxide in cystic fibrosis","volume":"75","author":"Balfour-Lynn","year":"1996","journal-title":"Archives of Disease in Childhood"},{"issue":"3","key":"10.1016\/j.jcf.2023.05.015_bib0002","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/(SICI)1099-0496(199709)24:3<173::AID-PPUL2>3.0.CO;2-O","article-title":"Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis","volume":"24","author":"Grasemann","year":"1997","journal-title":"Pediatric pulmonology"},{"issue":"1","key":"10.1016\/j.jcf.2023.05.015_bib0003","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jcf.2017.05.005","article-title":"Lower exhaled nitric oxide in infants with Cystic Fibrosis compared to healthy controls","volume":"17","author":"Korten","year":"2018","journal-title":"Journal of cystic fibrosis"},{"issue":"6","key":"10.1016\/j.jcf.2023.05.015_bib0004","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jcf.2015.07.001","article-title":"Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis","volume":"14","author":"Grasemann","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2023.05.015_bib0005","series-title":"Airway nitric oxide production in patients with cystic fibrosis increases with ivacaftor therapy","author":"Grasemann","year":"2015"},{"issue":"6","key":"10.1016\/j.jcf.2023.05.015_bib0006","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jcf.2015.07.002","article-title":"Concentration of fractional excretion of nitric oxide (FENO): A potential airway biomarker of restored CFTR function","volume":"14","author":"Kotha","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1016\/j.jcf.2023.05.015_bib0007","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01113-2019","article-title":"Long-term effect of CFTR modulator therapy on airway nitric oxide","volume":"55","author":"Grasemann","year":"2020","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1016\/j.jcf.2023.05.015_bib0008","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1016\/j.jcf.2023.05.015_bib0009","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1183\/09031936.00195512","article-title":"Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry","volume":"42","author":"Quanjer","year":"2013","journal-title":"European Respiratory Journal"},{"issue":"Suppl 3","key":"10.1016\/j.jcf.2023.05.015_bib0010","first-page":"S5","article-title":"Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the IL-1 signaling pathway","volume":"54","author":"Balazs","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.jcf.2023.05.015_bib0011","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jcf.2018.05.006","article-title":"Interleukin-1 is associated with inflammation and structural lung disease in young children with cystic fibrosis","volume":"17","author":"Montgomery","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2023.05.015_bib0012","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jcf.2022.02.017","article-title":"Interleukin-1 beta is a potential mediator of airway nitric oxide deficiency in cystic fibrosis","volume":"21","author":"Nissen","year":"2022","journal-title":"Journal of cystic fibrosis"},{"key":"10.1016\/j.jcf.2023.05.015_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1096242","article-title":"Loss of CFTR function is associated with reduced bitter taste receptor-stimulated nitric oxide innate immune responses in nasal epithelial cells and macrophages","volume":"14","author":"Carey","year":"2023","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jcf.2023.05.015_bib0014","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S2213-2600(13)70182-6","article-title":"Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial","volume":"1","author":"Davies","year":"2013","journal-title":"The Lancet Respiratory Medicine"},{"issue":"12","key":"10.1016\/j.jcf.2023.05.015_bib0015","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/ppul.20730","article-title":"Alveolar, but not bronchial nitric oxide production is elevated in cystic fibrosis","volume":"42","author":"Suri","year":"2007","journal-title":"Pediatric pulmonology"},{"issue":"1","key":"10.1016\/j.jcf.2023.05.015_bib0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1006\/bbrc.2001.4935","article-title":"S-nitrosoglutathione increases cystic fibrosis transmembrane regulator maturation","volume":"284","author":"Zaman","year":"2001","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323001455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323001455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:11:30Z","timestamp":1767240690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323001455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1569199323001455"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.05.015","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elexacaftor-tezacaftor-ivacaftor increases airway nitric oxide in children with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}